Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire
2025.11.14 13:08

APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma ...